Clinical Trial Update: Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating icotinib as adjuvant therapy versus standard chemotherapy in stage II-IIIA non-small cell lung cancer with EGFR mutations; current stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: UNKNOWN